Related references
Note: Only part of the references are listed.Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura
Marie Scully et al.
BLOOD (2017)
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Flora Peyvandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura
Filip Callewaert et al.
BLOOD (2012)
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
Hans Ulrichts et al.
BLOOD (2011)
Share Paper
